Identification and Validation of Prognostically Relevant Gene Signature in Melanoma

Table 4

Identification of prognostic-related clinical factors and clinical independence using univariate and multivariate Cox regression analyses in the TCGA training set, TCGA test set, GSE19234, and GSE65904.

Variables	Univariate analysis			Multivariable analysis
	HR	95% CI of HR	value	HR	95% CI of HR	value
TCGA training datasets
6-gene risk score
Low-risk group	1 (reference)			1 (reference)
High-risk group	2.81	1.91-4.14	1.63E-07	1.87	1.11-3.14	0.018
Age	1.03	1.01-1.04	1.76E-05	1.02	1.001-1.03	0.03736
Gender female	1 (reference)
Gender male	1.14	0.77-1.67	0.51	0.98	0.61-1.58	0.941573
Pathologic T1	1 (reference)			1 (reference)
Pathologic T2	2.24	0.90-5.53	0.08	1.88	0.68-5.21	0.227
Pathologic T3	2.99	1.22-7.3	0.02	5.52	1.50-20.24	0.01
Pathologic T4	5.75	2.36-13.96	1.10E-04	11.88	3.31-42.52	1.43E-04
Pathologic N0	1 (reference)			1 (reference)
Pathologic N1	1.49	0.85-2.61	0.163	2.58	0.31-20.90	0.374
Pathologic N2	1.94	1.06-3.55	0.03	2.6	0.31-21.56	0.375
Pathologic N3	2.68	1.53-4.67	5.30E-04	7.35	0.88-60.98	0.065
Pathologic M0	1 (reference)			1 (reference)
Pathologic M1	1.66	0.83-3.28	0.151	1.26	0.42-3.74	0.67
Tumor stage I	1 (reference)			1 (reference)
Tumor stage II	1.64	0.92-2.89	0.089	0.28	0.092-0.82	0.022
Tumor stage III/IV	2.25	1.32-3.79	0.002	0.22	0.024-2.0024	0.18
Validation cohort, TCGA test datasets, GSE19234, and GSE65904
TCGA test datasets
6-gene risk score
Low-risk group	1 (reference)			1 (reference)
High-risk group	1.54	1.04-2.26	0.029	1.41	0.86-2.29	0.166
Age	1.02	1.007-1.034	0.003	1.01	0.99-1.02	0.223
Gender female	1 (reference)			1 (reference)
Gender male	1.28	0.83-1.97	0.26	1.23	0.70-2.16	0.454
Pathologic T1	1 (reference)			1 (reference)
Pathologic T2	0.98	0.42-2.26	0.957	1.35	0.48-3.75	0.563
Pathologic T3	1.4	0.62-3.12	0.409	1.25	0.33-4.69	0.737
Pathologic T4	2.47	1.13-5.36	0.023	2.3	0.62-8.45	0.21
Pathologic N0	1 (reference)			1 (reference)
Pathologic N1	1.46	0.85-2.49	0.168	2.12	0.57-7.94	0.261
Pathologic N2	1.11	0.54-2.24	0.78	2.29	0.57-9.12	0.237
Pathologic N3	3	1.47-6.09	0.002	5.86	1.4-24.53	0.015
Pathologic M0	1 (reference)			1 (reference)
Pathologic M1	4.35	1.01-18.62	0.047	5.307	0.54-51.81	0.151
Tumor stage I	1 (reference)			1 (reference)
Tumor stage II	1.51	0.83-2.73	0.172	1.14	0.37-3.5	0.813
Tumor stage III/IV	1.86	1.06-3.28	0.03	0.88	0.18-4.21	0.882
GSE19234
6-gene risk score
Low-risk group	1 (reference)			1 (reference)
High-risk group	3.22	1.18-8.76	0.022	3.34	1.2-9.3	0.021
Age	1.01	0.98-1.02	0.579	1	0.97-1.023	1
Gender female	1 (reference)			1 (reference)
Gender male	0.76	0.33-1.75	0.526	0.93	0.4-2.15	0.868
Tumor stage III	1 (reference)			1 (reference)
Tumor stage IV	4.03	1.43-11.38	0.008	4.29	1.46-12.56	0.008
GSE65904
6-gene risk score
Low-risk group	1 (reference)			1 (reference)
High-risk group	1.53	1.036-2.265	0.032	1.492	1.002-2.220	0.0488
Age	0.998	0.984-1.012	0.796	1.001	0.987-1.015	0.927
Gender female	1 (reference)			1 (reference)
Gender male	0.748	0.496-1.13	0.169	0.788	0.522-1.192	0.259